Sun Acquisitions

AUGUST 5, 2024

Technology enables more efficient due diligence, valuation, and integration, helping companies identify opportunities and mitigate risks more effectively. Focus on ESG (Environmental, Social, and Governance) Factors: In recent years, there has been a notable shift towards incorporating ESG considerations into M&A decision-making.

M&A 59

M&A Mergers and Acquisitions IPO Valuation 59

MergersCorp M&A International

OCTOBER 15, 2024

SPACs are publicly traded companies that raise capital through an initial public offering (IPO) with the primary aim of acquiring an existing private company, thereby enabling it to go public without undergoing the traditional IPO process.

Mergers and Acquisitions 52

Mergers and Acquisitions Advisory IPO Initial Public Offering 52

Cooley M&A

MARCH 1, 2019

Even for a thriving business with a viable equity story, committed stakeholders and the right advisers, the final deal terms and valuation are typically guided by factors beyond a company’s control. Stock market forces also make the timing of an eventual outright exit and the final blended valuation of equity sales over time uncertain.

IPO 52

IPO Valuation M&A Business 52

Cooley M&A

MARCH 22, 2023

With the US initial public offering markets continuing to remain largely closed, and special purpose acquisition company combinations being costly and complex, there’s a new kid in town for foreign companies looking to go public in the US: reverse mergers.

Mergers 52

Mergers IT Mergers and Acquisitions IPO 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. Of course, we continue to see many parties discussing licensing deals deciding to do just that – turning to a full acquisition after initial licensing discussions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 30, 2024

These dynamics help explain why, despite significant sector-wide declines in public tech and life sciences company valuations from 2021 peaks, we have yet to mark a dramatic increase in activism campaigns relative to historical levels: for many would-be targets, there was no clear “fix” available. Jonathan Milner’s campaign at Abcam.

Private Equity 52

Private Equity M&A Capital Investors 52

Cooley M&A

JANUARY 25, 2023

However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined private equity sponsor buyers. trillion. [2]

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52